CIBC Private Wealth Group LLC Raises Stock Position in Becton, Dickinson and Company $BDX

CIBC Private Wealth Group LLC lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.9% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 111,993 shares of the medical instruments supplier’s stock after buying an additional 3,201 shares during the period. CIBC Private Wealth Group LLC’s holdings in Becton, Dickinson and Company were worth $20,962,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its stake in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares in the last quarter. Empowered Funds LLC raised its holdings in shares of Becton, Dickinson and Company by 20.4% during the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after buying an additional 1,354 shares during the period. United Bank lifted its position in Becton, Dickinson and Company by 23.9% during the 2nd quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock worth $887,000 after acquiring an additional 993 shares in the last quarter. Cetera Investment Advisers lifted its position in Becton, Dickinson and Company by 6.0% during the 2nd quarter. Cetera Investment Advisers now owns 83,538 shares of the medical instruments supplier’s stock worth $14,389,000 after acquiring an additional 4,700 shares in the last quarter. Finally, Rothschild Investment LLC boosted its holdings in Becton, Dickinson and Company by 10.5% in the 2nd quarter. Rothschild Investment LLC now owns 728 shares of the medical instruments supplier’s stock worth $125,000 after acquiring an additional 69 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on BDX shares. TD Cowen lifted their price objective on shares of Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a research note on Wednesday, February 11th. JPMorgan Chase & Co. decreased their target price on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a research note on Tuesday, February 10th. Bank of America raised their price target on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a report on Monday, January 5th. Morgan Stanley lifted their price target on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Finally, Stifel Nicolaus upped their price objective on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Five research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $195.46.

Becton, Dickinson and Company Stock Down 1.0%

Shares of NYSE:BDX opened at $156.56 on Friday. The firm has a market cap of $44.58 billion, a PE ratio of 25.54, a price-to-earnings-growth ratio of 11.46 and a beta of 0.24. The company has a fifty day simple moving average of $186.50 and a 200 day simple moving average of $189.08. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. The firm had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The firm’s revenue was up 1.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 68.52%.

Becton, Dickinson and Company declared that its Board of Directors has initiated a stock buyback program on Tuesday, January 27th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the medical instruments supplier to purchase up to 0% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the sale, the executive vice president owned 12,095 shares in the company, valued at $2,509,228.70. This represents a 11.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Bertram L. Scott sold 953 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the transaction, the director directly owned 36,763 shares in the company, valued at approximately $6,713,291.43. This represents a 2.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 2,787 shares of company stock worth $551,391 in the last ninety days. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.